Scientists are exploring new types of medications to treat Alzheimer’s disease. The Green Memory study is novel, as it focuses on targeting the gut’s microbiome to determine if rebalancing certain bacteria with a naturally derived investigational medication would improve brain function and slow the progression of Alzheimer’s disease. This investigational medication has been approved for use treating Alzheimer’s disease outside the U.S., and the Green Memory study is now being tested in the U.S.
Approximately 80 research clinics across North America are working on the Green Memory study. Over half of these clinics are a part of GAP-Net, the Global Alzheimer’s Platform Foundation® (GAP) network of nearly 80 clinical research sites in North America which benefit from sharing knowledge and experience in order to effectively and efficiently work toward research progress in neurodegenerative conditions. To complete the Green Memory study, research centers need more than 2,000 volunteers—including The Cognitive and Research Center of New Jersey.
Volunteers for the Green Memory study must meet the following qualifications:
- Be between the ages of 50 and 85.
- Have been diagnosed with mild to moderate Alzheimer’s disease.
- Have a study partner who knows you well, is with you three or more days a week, and can come to all study-related visits.
If you choose to participate in the Green Memory study, you will:
- Receive individualized attention from brain health experts.
- Be part of the team that is helping to find treatments for Alzheimer’s disease.
- Help future generations and honor people who had the disease.
The Green Memory study involves taking three capsules of the investigational medication by mouth twice a day, and six visits to The Cognitive and Research Center of New Jersey over a year of treatment – as well as four visits conducted over the phone. If you want to be a part of the future of Alzheimer’s disease research and you meet the qualifications, please get in touch with The Cognitive and Research Center of New Jersey. We want to hear from you. Our research team can happily answer any questions you might have and give you more information about Alzheimer’s disease research and the Green Memory study.
For more information:
Phase 3 Clinical Trial: A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer’s Disease (GREEN MEMORY). Sponsor: Shanghai Greenvalley Pharmaceutical Co., Ltd. Last update: November, 2020. ClinicalTrials.gov Identifier: NCT04520412. Accessed Jan 19, 2021.
The Green Memory Study: A Global Alzheimer’s Platform Foundation® (GAP) Media Toolkit. © 2021 Global Alzheimer’s Platform Foundation. All rights reserved. https://globalalzplatform.org/ accessed January 20, 2021.